CR10227A - Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar - Google Patents

Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar

Info

Publication number
CR10227A
CR10227A CR10227A CR10227A CR10227A CR 10227 A CR10227 A CR 10227A CR 10227 A CR10227 A CR 10227A CR 10227 A CR10227 A CR 10227A CR 10227 A CR10227 A CR 10227A
Authority
CR
Costa Rica
Prior art keywords
hydroxy
acid
methoxyphenylcarbamoyl
dihydroquinolin
piperidin
Prior art date
Application number
CR10227A
Other languages
English (en)
Spanish (es)
Inventor
Reshma Chudasama
Andrew Kennedy
Leanda Jane Kindon
Franck Patrick Mallet
Original Assignee
Glaxo Group Ltd
Rafael Eduardo Meneses Quintana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, Rafael Eduardo Meneses Quintana filed Critical Glaxo Group Ltd
Publication of CR10227A publication Critical patent/CR10227A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR10227A 2006-02-10 2008-08-20 Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar CR10227A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
CR10227A true CR10227A (es) 2008-10-29

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10227A CR10227A (es) 2006-02-10 2008-08-20 Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar

Country Status (33)

Country Link
US (1) US7960551B2 (OSRAM)
EP (1) EP1981872B1 (OSRAM)
JP (1) JP5616021B2 (OSRAM)
KR (1) KR101488691B1 (OSRAM)
CN (1) CN101379057B (OSRAM)
AR (2) AR059409A1 (OSRAM)
AU (1) AU2007213767B2 (OSRAM)
BR (1) BRPI0707559B8 (OSRAM)
CA (1) CA2641769C (OSRAM)
CR (1) CR10227A (OSRAM)
CY (1) CY1119238T1 (OSRAM)
DK (1) DK1981872T3 (OSRAM)
EA (1) EA016580B1 (OSRAM)
ES (1) ES2640226T3 (OSRAM)
GB (1) GB0602778D0 (OSRAM)
HR (1) HRP20171304T1 (OSRAM)
HU (1) HUE034315T2 (OSRAM)
IL (1) IL193103A (OSRAM)
JO (1) JO3389B1 (OSRAM)
LT (1) LT1981872T (OSRAM)
MA (1) MA30273B1 (OSRAM)
MY (1) MY153656A (OSRAM)
NO (1) NO341343B1 (OSRAM)
NZ (1) NZ570242A (OSRAM)
PE (2) PE20110120A1 (OSRAM)
PL (1) PL1981872T3 (OSRAM)
PT (1) PT1981872T (OSRAM)
SG (1) SG169404A1 (OSRAM)
SI (1) SI1981872T1 (OSRAM)
TW (1) TWI401251B (OSRAM)
UA (1) UA100364C2 (OSRAM)
WO (1) WO2007090859A1 (OSRAM)
ZA (1) ZA200806782B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022030B1 (ru) 2009-04-14 2015-10-30 Глаксо Груп Лимитед Способ получения 1-[2-(2-хлор-4-формил-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты
DK2599778T3 (en) 2009-04-23 2017-06-26 Theravance Respiratory Co Llc Diamide compounds with muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activity
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
CA2842276C (en) * 2011-08-02 2020-11-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
HK1215166A1 (zh) * 2012-12-18 2016-08-19 Almirall, S.A. 具有β2肾上腺素激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022776A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
SK116394A3 (en) 1992-03-31 1995-04-12 Glaxo Group Ltd Substituted phenylcarbamates and ureas
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US6130232A (en) 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的5−ht1a、5−ht1bおよび5−ht1d受容体アンタゴニストとしてのそれらの用途
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO1999064043A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Muscarinic receptor antagonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
BR0111440A (pt) 2000-06-05 2003-06-03 Altana Pharma Ag Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PL213489B1 (pl) 2002-04-12 2013-03-29 Boehringer Ingelheim Pharma Kompozycje farmaceutyczne zawierajace betamimetyk i nowy lek antycholinergiczny oraz zastosowanie kompozycji
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ2アドレナリン作動性レセプターアゴニスト
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
AU2007213767A1 (en) 2007-08-16
SI1981872T1 (sl) 2017-10-30
BRPI0707559B1 (pt) 2021-01-12
CA2641769A1 (en) 2007-08-16
US20070281971A1 (en) 2007-12-06
KR101488691B1 (ko) 2015-02-02
AR059409A1 (es) 2008-04-09
ES2640226T3 (es) 2017-11-02
EP1981872A1 (en) 2008-10-22
WO2007090859A1 (en) 2007-08-16
TW200800948A (en) 2008-01-01
EA200801691A1 (ru) 2009-02-27
HRP20171304T1 (hr) 2017-10-20
IL193103A0 (en) 2009-02-11
EP1981872B1 (en) 2017-06-21
JP5616021B2 (ja) 2014-10-29
GB0602778D0 (en) 2006-03-22
DK1981872T3 (en) 2017-09-11
SG169404A1 (en) 2011-03-30
JO3389B1 (ar) 2019-03-13
MY153656A (en) 2015-03-13
CN101379057B (zh) 2013-02-13
LT1981872T (lt) 2017-09-11
AU2007213767B2 (en) 2012-04-26
CN101379057A (zh) 2009-03-04
BRPI0707559A8 (pt) 2019-01-29
NO20083425L (no) 2008-09-09
AR104288A2 (es) 2017-07-12
CY1119238T1 (el) 2018-02-14
NO341343B1 (no) 2017-10-16
CA2641769C (en) 2014-02-04
ZA200806782B (en) 2009-10-28
MA30273B1 (fr) 2009-03-02
US7960551B2 (en) 2011-06-14
EA016580B1 (ru) 2012-06-29
UA100364C2 (xx) 2012-12-25
HUE034315T2 (en) 2018-02-28
JP2009526018A (ja) 2009-07-16
IL193103A (en) 2013-06-27
NZ570242A (en) 2011-09-30
BRPI0707559B8 (pt) 2021-05-25
PE20110120A1 (es) 2011-03-08
PE20071249A1 (es) 2008-01-16
BRPI0707559A2 (pt) 2011-05-10
TWI401251B (zh) 2013-07-11
KR20080114723A (ko) 2008-12-31
PT1981872T (pt) 2017-09-13
PL1981872T3 (pl) 2017-11-30

Similar Documents

Publication Publication Date Title
CR10227A (es) Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar
AR051003A1 (es) Forma cristalina de un compuesto bifenilo
NO20092104L (no) Nye 1,2-dihydroquinolinderivater, farmasøytisk sammensetning inneholdende slike, samt anvendelse derav
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BRPI0718860A2 (pt) composição virucida e método para matar vírus
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
EP2497482A4 (en) COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUSED INDUCED DISEASES
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
EP2019687A4 (en) ANTI-STREPTOCOCCAL VACCINE
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
DK1893603T3 (da) Piperidin-4-YL-amidderivater og anvendelsen deraf som SST-receptorundertype 5-antagonister
DK2271321T3 (da) Farmaceutisk sammensætning 271
CL2007002315A1 (es) Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable.
AR058105A1 (es) Derivados de piperazina utiles como agonistas de ccr5
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
IL205981A0 (en) 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID ã?-LACTONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE
BRPI0821922A2 (pt) Derivado esteroide de gama-lactona de ácido 17-hidróxi-19-nor-21-carboxílico, uso do mesmo e medicamento que contém o derivado
UY29714A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
CL2007003574A1 (es) 4-((1r,3r)-1-(3,5-difluorofenil)-3-(4-(3-etil-5-isopropil-4h-1,2,4-triazol-4-il)piperidin-1-il)butil)-1-(metilsulfonil)piperidina; su proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de una
CL2010001489A1 (es) Compuestos derivados de isoquinolinas mediadores de rho-quinasa; composición farmacéutica que comprende dichos compuestos; uso en el tratamiento o prevención de la hipertensión, hipertensión pulmonar, insuficiencia cardíaca, epoc, diabetes, enfermedades autoinmunes, sida, entre otras.
ITTO20060350A1 (it) Dispositivo per la fermentazione malolattica e relativo procedimento
CR20140109S (es) Composiciones farmaceuticas estabilizadoras que comprenden fesoterodina
RU2006112432A (ru) Противоишемический препарат
ITAT20060010A1 (it) "prendi appunti" per agende e rubriche.

Legal Events

Date Code Title Description
FC Refusal